Motavizumab, Nirsevimab, Palivizumab Beneficial for RSV Prevention
Significant reductions seen in RSV-related infections, RSV-related hospitalizations for three monoclonal antibodies versus placebo
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.